US4990336A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release dosage form
Assignee: BIOTECHNOLOGY MANAGEMENT ASSOCIATES Inc
•
Filing: 1989-02-08
•
Granted: 1991-02-05
•
Expires: 2009-02-08
Abstract
Abstract A multiphasic sustained release injectable delivery system is provided, as well as a method for treating humans and other mammals with that multiphasic sustained release system. The multiphasic sustained release system comprises prolonged, controlled delivery of microencapsulated allergen extract comprising allergen extract encapsulated in microcapsules of bioerodible encapsulating polymer, which permits a subtained, multiphasic release of said allergen extract, including (i) a first portion of allergen extract that upon injection is capable of being released from said microcapsules of bioerodible encapsulating polymer in a manner whereby only a relatively small amount of said allergen extract is released during said first phase, whereby initial allergenicity is minimized due to said first portion producing a mild local reaction similar to that normally observed with low doses of conventional allergen administration; and (ii) secondary portions of allergen extract that provide a substantially higher level of allergen extract in doses which could provoke a serious reaction in the patient, but for the prior release of said first portion.
Inventors
- 👤 Loui J. Silvestri
- 👤 H. Ruth Pyle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 06:29
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5005; A61K9/5021; A61K9/5031
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
143 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract comprising allergen extract encapsulated in microcapsules of bioerodible encapsulating polymer, which permits a sustained, multiphasic release of said allergen extract, including: (i) a first portion of allergen extract that upon injection is released from said microcapsules of bioerodible encapsulating polymer in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of allergen extract that is released from said microcapsules to provide a level of allergen extract in doses which could provoke a serious reaction in the patient had the first portion not been administrated; wherein said bioerodible encapsulating polymer is selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanhydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, polyglutamates, and copolymers and combinations thereof.
Claim 2
Dependent Claim
143 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract comprising allergen extract encapsulated in microcapsules of bioerodible encapsulating polymer, which permits a sustained, multiphasic release of said allergen extract, including: (i) a first portion of allergen extract that upon injection is released from said microcapsules of bioerodible encapsulating polymer in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of allergen extract that is released from said microcapsules to provide a level of allergen extract in doses which could provoke a serious reaction in the patient had the first portion not been administrated; wherein said bioerodible encapsulating polymer is selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanhydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, polyglutamates, and copolymers and combinations thereof.
Claim 3
Dependent Claim
55 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract in accordance with claim 1, wherein the total amount of allergen extract in said second portion is at a level higher than the toxic level for said allergen extract, in the absence of the prior release of said first portion.
Claim 4
Dependent Claim
45 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract in accordance with claim 1 further comprising an antiallergic agent and, wherein the serious reaction caused by the released allergens is controlled by the synchronous release of said antiallergic agent.
Claim 5
Dependent Claim
30 words
A multiphasic sustained release injectable delivery system of claim 3 wherein said antiallergic agent is selected from the group consisting of diphenhydramine, chlorpheniramine, clemastine, hydroxyzine, terfenadine, promethazine and cromolyn sodium.
Claim 6
Dependent Claim
47 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract of claim 1, wherein said allergen extract is of an allergen selected from the group consisting of a pollen, mold, food, animal dander, animal excretion, smut, insect, insect venom and insect excretions.
Claim 7
Dependent Claim
132 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract of claim 1, wherein the multiphasic release rate is achieved by providing a heterogeneous mixture of microspheres of bioerodible encapsulating polymers, a portion of said microspheres corresponding to the first portion (i) being selected from the group consisting of: a. microspheres having thinner allergen-impregnated polymer layers relative to the microspheres of the second portion (ii); b. microspheres having higher concentrations of bioerodible polymer relative to the microspheres of the second portion (ii); c. microspheres having lower concentrations of impregnated allergen relative to the microspheres of the second portion (ii); d. microspheres composed of bioerodible polymers with an intrinsically different means or rate of bioerosion relative to the microspheres of the second portion (ii); and e. combinations thereof.
Claim 8
Dependent Claim
203 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract of claim 1, wherein the multiphasic release rate is homgeneously achieved by using only one of the following types of microspheres selected from the group consisting of: a. microspheres which have thicker allergen-impregnated outer polymer layers relative to allergen-impregnated layers in the core; b. microspheres in which there is a higher concentration of polymer in the outer layers of the microsphere relative to the core of the microsphere; c. microspheres which have different ratios of copolymers in the outer layers relative to the core; d. microspheres in which the outer layers are made of a first class of bioerodible polymer, and in which the core of each microsphere is made of a second class of bioerodible polymer with an intrinsically different means or rate of bioerosion relative to said first class of bioerodible polymer; and e. microspheres in which the outer layers of each microsphere contains a lower concentration of impregnated allergen relative to the core of each microsphere, wherein the allergen extract of the first portion (i) is contained in the outer layers and the allergen extract of the second portion (ii) is contained in the core.
Claim 9
Dependent Claim
67 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract of claim 1, wherein the multiphasic release rate is achieved by providing a mixture of microspheres, those corresponding to said first portion (i) including hydrolysis retarding agents impregnated in the microsphere polymer layers, while the microspheres corresponding to said second portion (ii) contain hydrolysis accelerating agents, or no accelerating agent at all.
Claim 10
Dependent Claim
40 words
A multiphasic sustained release injectable delivery system of claim 8 wherein said hydrolysis retarding and accelerating agents are each selected from the group consisting of pharmaceutically acceptable organic acids and bases, acidic, neutral and basic inorganic salts, and solutions thereof.
Claim 11
Dependent Claim
21 words
A multiphasic sustained release injectable delivery system of claim 1 wherein an allergen stabilizing agent is encapsulated along with the allergen.
Claim 12
Dependent Claim
27 words
A multiphasic sustained release injectable delivery system of claim 10 wherein said allergen stabilizing agent is a thermopreservative selected from the group consisting of glycerine and mannitol.
Claim 13
Dependent Claim
19 words
A multiphasic sustained release injectable delivery system of claim 1 wherein an adjuvant is encapsulated along with the allergen.
Claim 14
Dependent Claim
26 words
A multiphasic sustained release injectable delivery system of claim 12 wherein said adjuvant is selected from the group consisting of tyrosine, polytyrosine, dimethylglycine, and muramyl dipeptide.
Claim 15
Dependent Claim
18 words
A multiphasic sustained release injectable delivery system of claim 1 wherein the encapsulated allergen is in aqueous form.
Claim 16
Dependent Claim
18 words
A multiphasic sustained release injectable delivery system of claim 1 wherein the encapsulated allergen is in lyophilized form.
Claim 17
Dependent Claim
19 words
A multiphasic sustained release injectable delivery system of claim 1 wherein the encapsulated allergen is physically or chemically modified.
Claim 18
Independent Claim
120 words
A method of allergen desensitization therapy which comprises injecting a subject with microencapsulated allergen extract, wherein (i) a first portion of allergen extract is released from said microcapsules in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of allergen extract is released from said microcapsules to provide a level of allergen extract in doses which could provoke a serious reaction in the patient, had the first portion not been administrated; wherein said allergen extract is encapsulated in a bioerodible encapsulating polymer selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanhydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, poly-glutamates, and copolymers or combinations thereof.
Claim 19
Independent Claim
120 words
A method of allergen desensitization therapy which comprises injecting a subject with microencapsulated allergen extract, wherein (i) a first portion of allergen extract is released from said microcapsules in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of allergen extract is released from said microcapsules to provide a level of allergen extract in doses which could provoke a serious reaction in the patient, had the first portion not been administrated; wherein said allergen extract is encapsulated in a bioerodible encapsulating polymer selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanhydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, poly-glutamates, and copolymers or combinations thereof.
Claim 20
Dependent Claim
70 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract of claim 1, wherein the multiphasic release rate is achieved by providing a mixture of microspheres, wherein those microspheres corresponding to said second portion (ii) contain hydrolysis accelerating agents, whereas those microspheres corresponding to said first portion (i) either include hydrolysis retarding agents impregnated in the microsphere polymer layers, or include no hydrolysis retarding agents.
Claim 21
Dependent Claim
40 words
A multiphasic sustained release injectable delivery system of claim 18 wherein said hydrolysis retarding and accelerating agents are each selected from the group consisting of pharmaceutically acceptable organic acids and bases, acidic, neutral and basic inorganic salts, and solutions thereof.
Claim 22
Dependent Claim
153 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract comprising unextracted allergen source material encapsulated in microcapsules of bioerodible encapsulating polymer, which permits a sustained multiphasic release of said unextracted allergen source material, including: (i) a first portion of unextracted allergen source material that upon injection is released from said microcapsules of bioerodible encapsulating polymer in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of unextracted allergen source material that is released from said microcapsules to provide a level of unextracted allergen source material in doses which could provoke a serious reaction in the patient, had the first portion not been administrated; wherein said bioerodible encapsulating polymer is selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanbydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, polyglutamates, and copolymers or combinations thereof.
Claim 23
Dependent Claim
153 words
A multiphasic sustained release injectable delivery system for prolonged, controlled delivery of microencapsulated allergen extract comprising unextracted allergen source material encapsulated in microcapsules of bioerodible encapsulating polymer, which permits a sustained multiphasic release of said unextracted allergen source material, including: (i) a first portion of unextracted allergen source material that upon injection is released from said microcapsules of bioerodible encapsulating polymer in a quantity sufficient to stimulate an immune response, but insufficient to trigger serious allergenic adverse reactions; and (ii) a second portion of unextracted allergen source material that is released from said microcapsules to provide a level of unextracted allergen source material in doses which could provoke a serious reaction in the patient, had the first portion not been administrated; wherein said bioerodible encapsulating polymer is selected from the group consisting of poly(lactides), poly(glycolides), non-peptide polyamino acids, poly(ortho esters), polyanbydrides, polyiminocarbonates, poly(alpha-aminoacids), polyalkyl-cyano-acrylate, polyphosphazenes, acyloxymethyl polyaspartates, polyglutamates, and copolymers or combinations thereof.
References Cited (Backward Citations)
US3329574A
Cited
US4226853A
Cited
US3541201A
Cited
US3794630A
Cited
US3825525A
Cited
US3893993A
Cited
US3903067A
Cited
US3773919A
Cited
US3761585A
Cited
US3792159A
Cited
US4021364A
Cited
US4180562A
Cited
US4351337A
Cited
US3976071A
Cited
US4070455A
Cited
US3978203A
Cited
US4131648A
Cited
US4093709A
Cited
US4261973A
Cited
US4158705A
Cited
US4140679A
Cited
US4164560A
Cited
US4391797A
Cited
US4489055A
Cited
US4329332A
Cited
US4256732A
Cited
US4215036A
Cited
US4222907A
Cited
US4234569A
Cited
US4220565A
Cited
US4276206A
Cited
US4269764A
Cited
US4293539A
Cited
US4253996A
Cited
US4338297A
Cited
US4439199A
Cited
US4469677A
Cited
US4609547A
Cited
US4675189A
Cited
US4767628B1
Cited
US4767628A
Cited
US4428932A
Cited
US4713249A
Cited
US4526938A
Cited
US4489056A
Cited
US4675381A
Cited
US4683288A
Cited
US4774074A
Cited
US4638045A
Cited
US4713244A
Cited
US4741872A
Cited
US4757128A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-04 | 1994-08-06 | 1995-02-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-04 | 1998-08-06 | 1999-02-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-04 | 2002-08-06 | 2003-02-05 | $7700.00 | Window Closed / Lapsed |